Common use of Data Publication Clause in Contracts

Data Publication. Eisai shall not publish nor otherwise publicly disclose any data or results regarding any Compound or Product without the prior written consent of Roivant, provided that with respect to the proposed eight articles on Exhibit D listed as in process but not yet published on or prior to the Effective Date, Roivant shall have the right to (a) review each not less than [***] prior to intended submission for publication, or if such date has passed as of the Effective Date, within [***] after the Effective Date, and (b) comment on each article prior to its submission. If Roivant wishes to publish peer reviewed manuscripts disclosing the results of studies carried out under this Agreement provided that such publication does not disclose any of Eisai’s Confidential Information, it shall provide Eisai with the opportunity to review and [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. EXECUTION VERSION Confidential comment on any proposed publication which relates to the Product at least [***] prior to its intended submission for publication. Roivant shall: (i) consider in good faith any comments thereto provided by Eisai within such [***] period; and (ii) remove any Confidential Information of Eisai identified by Eisai as part of its review.

Data Publication. Eisai shall not publish nor otherwise publicly disclose any data or results regarding any Compound or Product without the prior written consent of Roivant, provided that with respect to the proposed eight articles on Exhibit D listed as in process but not yet published on or prior to the Effective Date, Roivant shall have the right to (a) review each not less than [***] prior to intended submission for publication, or if such date has passed as of the Effective Date, within [***] after the Effective Date, and (b) comment on each article prior to its submission. If Roivant wishes to publish peer reviewed manuscripts disclosing the results of studies carried out under this Agreement provided that such publication does not disclose any of Eisai’s Confidential Information, it shall provide Eisai with the opportunity to review and [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS[***], HAS BEEN OMITTED BECAUSE DERMAVANT SCIENCES LTD. HAS DETERMINED THE INFORMATION (I) IS FILED WITH THE SECURITIES NOT MATERIAL AND EXCHANGE COMMISSION PURSUANT (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDEDDERMAVANT SCIENCES LTD. IF PUBLICLY DISCLOSED. EXECUTION VERSION Confidential comment on any proposed publication which relates to the Product at least [***] prior to its intended submission for publication. Roivant shall: (i) consider in good faith any comments thereto provided by Eisai within such [***] period; and (ii) remove any Confidential Information of Eisai identified by Eisai as part of its review.